Gastrointestinal Cancer Specialty Channel

Gastrointestinal Cancer

Specialty Channel

FDA Approval

FDA Approves Zolbetuximab Plus Chemotherapy for Patients With HER2-Negative Gastric/Gastroesophageal Junction Adenocarcinoma With CLDN18.2-Positive Tumors

10/18/2024

Stephanie Holland ;

Based on results from the SPOTLIGHT and GLOW trials, the FDA has approved first-line zolbetuximab plus fluoropyrimidine and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-negative gastric...

Based on results from the...

10/18/2024

Oncology

Conference Coverage

First-Line Retifanlimab Added to Standard of Care Chemotherapy Significantly Improves PFS in Anal Cancer

09/14/2024

Janelle Bradley ;

Findings from the phase 3 PODIUM-303 study suggest retifanlimab plus chemotherapy as a new standard of care for the first-line treatment of locally recurrent or metastatic squamous cell carcinoma of the anal canal.

Findings from the phase 3...

09/14/2024

Oncology

News

Nanoliposomal Irinotecan With Fluorouracil and Leucovorin Showed Promise for Patients With Advanced Cholangiocarcinoma

08/09/2024

Stephanie Holland ;

According to results from the phase 2 NIFE study, nanoliposomal irinotecan with fluorouracil and leucovorin in the first-line setting demonstrated efficacy and safety among patients with advanced, unresectable cholangiocarcinoma.

According to results from the...

08/09/2024

Oncology

News

Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

05/23/2024

Stephanie Holland

According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...

According to results from the...

05/23/2024

Oncology

News

Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

04/24/2024

Stephanie Holland

Based on results from the NETTER-P and NETTER-1 studies, the FDA has approved lutetium Lu 177 dotatate for pediatric patients aged 12 and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.

Based on results from the...

04/24/2024

Oncology

News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated approval to trastuzumab deruxtecan for patients with unresectable or metastatic HER2-positive solid tumors who have received systemic treatment and have no alternative treatment options.

The FDA granted accelerated...

04/08/2024

Oncology

Conference Coverage

Randomized Study Demonstrates Efficay of [177Lu] Lu-DOTA-TATE in First-Line Setting for Advanced Gastroenteropancreatic Neuroendocrine Tumors

01/19/2024

Stephanie Holland ;

According to primary analysis results from the phase 3 NETTER-2 study, first-line [177Lu] Lu-DOTA-TATE significantly prolonged PFS and demonstrated a clinically meaningful ORR among patients with newly diagnosed, advanced grade 2 and 3...

According to primary analysis...

01/19/2024

Oncology

Conference Coverage

Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer

01/19/2024

Janelle Bradley ;

First-line treatment with atezolizumab and bevacizumab plus chemotherapy provides PFS advantage vs atezolizumab plus placebo and chemotherapy for patients with advanced biliary tract cancer, according to findings from the phase 2 IMbrave151...

First-line treatment with...

01/19/2024

Oncology

Conference Coverage

Tiragolumab in Combination With Atezolizumab And Chemotherapy Shows Promise Among Patients With Esophageal Squamous Cell Carcinoma

01/18/2024

Allison Casey ;

According to results from the phase 3 SKYSCRAPER-08, tiragolumab plus atezolizumab and chemotherapy improved the progression-free survival and overall survival among patients with esophageal squamous cell carcinoma.

According to results from the...

01/18/2024

Oncology

News

Risk-Directed Thromboprophylaxis Reduced Thromboembolism and Mortality Among Patients With Gastrointestinal and Lung Cancer

10/16/2023

Allison Casey ;

In a phase 3 clinical trial, thrombosis rates of patients with gastrointestinal and lung cancer with high-risk profiles were mitigated to those comparable to the rates of patients with low-risk profiles with a risk-directed primary...

In a phase 3 clinical trial,...

10/16/2023

Oncology

News

Tucatinib Plus Trastuzumab Showed Promise Among Patients With HER2-Positive Metastatic Biliary Tract Cancer

10/13/2023

Allison Casey ;

According to results from a phase 2 basket study, tucatinib plus trastuzumab demonstrated antitumor activity and was well-tolerated among patients with previously treated HER2-positive metastatic biliary tract cancer.

According to results from a...

10/13/2023

Oncology

News

Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

05/23/2024

Stephanie Holland

According to results from the...

05/23/2024

Oncology

News

Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

04/24/2024

Stephanie Holland

Based on results from the...

04/24/2024

Oncology

News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated...

04/08/2024

Oncology

Conference Coverage

Randomized Study Demonstrates Efficay of [177Lu] Lu-DOTA-TATE in First-Line Setting for Advanced Gastroenteropancreatic Neuroendocrine Tumors

01/19/2024

Stephanie Holland ;

According to primary analysis...

01/19/2024

Oncology

Conference Coverage

Atezolizumab and Bevacizumab Plus Chemotherapy Provides Modest PFS Benefit in Advanced Biliary Tract Cancer

01/19/2024

Janelle Bradley ;

First-line treatment with...

01/19/2024

Oncology

Conference Coverage

Tiragolumab in Combination With Atezolizumab And Chemotherapy Shows Promise Among Patients With Esophageal Squamous Cell Carcinoma

01/18/2024

Allison Casey ;

According to results from the...

01/18/2024

Oncology

News

Risk-Directed Thromboprophylaxis Reduced Thromboembolism and Mortality Among Patients With Gastrointestinal and Lung Cancer

10/16/2023

Allison Casey ;

In a phase 3 clinical trial,...

10/16/2023

Oncology

News

Tucatinib Plus Trastuzumab Showed Promise Among Patients With HER2-Positive Metastatic Biliary Tract Cancer

10/13/2023

Allison Casey ;

According to results from a...

10/13/2023

Oncology

Videos

Bemarituzumab Plus FOLFOX Superior to FOLFOX Alone Among Patients With FGFR2b-Positive Metastatic Gastric Cancer

08/22/2023

Zev Wainberg , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presented results from the final analysis of the phase 2 FIGHT trial.

At the 2023 World Congress on...

08/22/2023

Oncology

Patrick Tan, MD, PhD, Genome Institute of Singapore

Videos

New Strategies for Molecular Classification in Gastric Cancer

08/22/2023

Patrick Tan , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Patrick Tan, MD, PhD, presented a keynote lecture on new strategies to achieve molecular classification in gastric cancer that can potentially inform the future treatment landscape.

At the 2023 World Congress on...

08/22/2023

Oncology

Interactive Features

Quiz

Quiz: Which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?

10/17/2022

Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?

Do you know which chemotherapy...

10/17/2022

Oncology

Test Your Knowledge

Quiz: Identifying Biliary Tract Cancers

09/08/2021

Which of the following uncommon cancers are classified as biliary tract cancers?

Which of the following uncommon...

09/08/2021

Oncology

Quiz

Quiz: Does Atorvastatin-Metformin Combo Reduce HCC Progression?

08/09/2021

True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...

True or false: The combination...

08/09/2021

Oncology

Test Your Knowledge

Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC

01/28/2021

True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.

True or false: Anlotinib has...

01/28/2021

Oncology

Test Your Knowledge

Quiz: Does Infigratinib Yield a Survival Benefit in Patients with Cholangiocarcinoma and FGFR2 Fusions?

08/28/2020

True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.

True or false: Infigratinib did...

08/28/2020

Oncology

Test Your Knowledge

Quiz: Is Avapritinib a Treatment Option for Patients with Unresectable PDGFRA D842V-Mutant GIST?

08/21/2020

True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.

True or false: In patients with...

08/21/2020

Oncology

Test Your Knowledge

Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?

08/21/2020

True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.

True or false: Classifying and...

08/21/2020

Oncology

Test Your Knowledge

Quiz: Is Oxaliplatin Superior to Mitomycin C During HIPEC for Colorectal Peritoneal Metastases?

07/31/2020

True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.

True or false: Overall survival...

07/31/2020

Oncology

Test Your Knowledge

Quiz: Can Plasma MDMs Accurately Detect Distant Recurrent CRC?

06/22/2020

True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.

True or False: MDMs in plasma...

06/22/2020

Oncology

Test Your Knowledge

Quiz: Should Pembrolizumab Be New Standard of Care for MSI-H/dMMR Metastatic CRC?

06/04/2020

True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?

True or False: Pembrolizumab...

06/04/2020

Oncology

Recent News

News

Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

05/23/2024

Stephanie Holland

According to results from the...

05/23/2024

Oncology

News

Lutetium Lu 177 Dotatate Gains FDA Approval for Pediatric Patients With SSTR-Positive Gastroenteropancreatic Neuroendocrine Tumors

04/24/2024

Stephanie Holland

Based on results from the...

04/24/2024

Oncology

News

FDA Grants Accelerated Approval to Trastuzumab Deruxtecan for Unresectable or Metastatic HER2-Positive Solid Tumors

04/08/2024

Stephanie Holland

The FDA granted accelerated...

04/08/2024

Oncology

Conference Coverage

Randomized Study Demonstrates Efficay of [177Lu] Lu-DOTA-TATE in First-Line Setting for Advanced Gastroenteropancreatic Neuroendocrine Tumors

01/19/2024

Stephanie Holland ;

According to primary analysis...

01/19/2024

Oncology

News

Risk-Directed Thromboprophylaxis Reduced Thromboembolism and Mortality Among Patients With Gastrointestinal and Lung Cancer

10/16/2023

Allison Casey ;

In a phase 3 clinical trial,...

10/16/2023

Oncology

News

Tucatinib Plus Trastuzumab Showed Promise Among Patients With HER2-Positive Metastatic Biliary Tract Cancer

10/13/2023

Allison Casey ;

According to results from a...

10/13/2023

Oncology

News

Trastuzumab Plus Ramucirumab and Paclitaxel Shows Promise Among Patients With Second-Line HER2-Positive, Advanced Gastric or Gastroesophageal Junction Cancer

08/10/2023

Allison Casey ;

In a phase 1b/2 study, trastuzumab plus ramucirumab and paclitaxel showed promise in the second-line setting for patients with HER2-positive gastric or gastroesophageal junction cancer.

In a phase 1b/2 study,...

08/10/2023

Oncology

News

Frontline Tislelizumab Plus Chemotherapy for Patients With Gastroesophageal Squamous Cell Carcinoma

05/23/2023

In a phase 3 trial, tislelizumab plus chemotherapy improved the overall survival of patients with advanced or metastatic gastroesophageal squamous cell carcinoma when compared with placebo plus chemotherapy.

In a phase 3 trial, tislelizumab...

05/23/2023

Oncology

News

Random Biopsies Essential for Endoscopic Surveillance of Patients with Hereditary Diffuse Gastric Cancer

01/19/2023

Allison Casey ;

Random biopsies were found to be an essential component to endoscopic surveillance for the detection of signet cell ring cell carcinoma foci as an indication of early-onset hereditary diffuse gastric cancer.

Random biopsies were found to be...

01/19/2023

Oncology

News

Impact of Early Discontinuation of Oxaliplatin Treatment in Patients With Colon Cancer Receiving Adjuvant Chemotherapy

12/01/2022

Allison Casey ;

While discontinuing all adjuvant chemotherapy in patients with colon cancer was found to have a negative impact on survival outcomes, discontinuing only oxaliplatin did not have a similar affect, according to a pooled analysis.

While discontinuing all adjuvant...

12/01/2022

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology